← Back to graph

Prescription

camizestrant investigational

Selected indexed studies

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. (Future Oncol, 2023) [PMID:37070653]
Second Oral SERD Shines in ER+ Breast Cancer. (Cancer Discov, 2023) [PMID:36661374]

_Worker-drafted node — pending editorial review._

Connections

No connections recorded yet.

Sources

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. (2023) pubmed
Second Oral SERD Shines in ER+ Breast Cancer. (2023) pubmed

Local graph